Avanir Pharmaceuticals, Inc.
) recently announced that the findings of the PRISM patient
registry (n= 5290) were published in a journal.
The data from the registry provided further clarity on the
prevalence and impact of pseudobulbar affect (PBA) in the
It was observed that PBA symptoms are quite prevalent among
patients with diverse neurological conditions.
We note that Avanir's Nuedexta is approved in the U.S. for the
treatment of PBA. In Jun 2013, Avanir received approval for
Nuedexta in the EU for the treatment of patients suffering from
The marketing application was based on controlled phase III
studies of Nuedexta in patients with PBA, plus data from
longer-term safety studies.
Nuedexta is also being studied for additional indications,
namely agitation in Alzheimer's disease (phase II), neuropathic
pain in multiple sclerosis (phase II) and
levodopa-induced-dyskinesia in Parkinson's disease (phase
We note that Avanir was in the news recently for its
Merck & Co., Inc.
) for the co-promotion of Merck's type II diabetes drug, Januvia
and the sitagliptin family of products in the U.S.
As per the deal, Avanir is entitled to receive fixed as well
as incentive-based payments. Avanir will promote the sitagliptin
family of products in long-term care institutions from Oct 2013.
Merck will also promote these products in all other settings.
Merck is also responsible for all other aspects such as research,
manufacturing and marketing of these products.
The deal is a major positive for Avanir. The collaboration
provides Avanir with funds in the form of fixed as well as
incentive payments. This deal not only brings Merck's leadership
in diabetes but also Avanir's well established sales force in the
Avanir currently carries a Zacks Rank #3 (Hold). Right now,
Jazz Pharmaceuticals Public Limited Company
) look well positioned, each with a Zacks Rank #2 (Buy).
AVANIR PHARM (AVNR): Free Stock Analysis
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis
MERCK & CO INC (MRK): Free Stock Analysis
SHIRE PLC-ADR (SHPG): Free Stock Analysis
To read this article on Zacks.com click here.